Article
作者: Xu, Dayong ; Zhang, Fengchun ; Yan, Jianshe ; An, Xingyan ; Xu, Sihuan ; Huang, Tao ; Chakrabarti, Sasanka ; Lim, Lee Wei ; Feng, Yingmei ; Zheng, Zhi ; Cano, Antonio ; Li, Jing ; Zhu, Rongjia ; Peng, Gongxin ; Ellison-Hughes, Georgina ; Liu, Jingqi ; Qu, Xuebin ; Jin, Ronghua ; Zhao, Robert Chunhua ; Su, Huanxing ; Yan, Tingdong ; Xu, Zhen ; Min, Kyung-Jin ; Moskalev, Alexey ; Gilson, Eric ; Wang, Jiao ; Stambler, Ilia ; Shan, Guangliang ; Zhang, Zhonghui ; Ma, Yan-Qing ; Cao, Yinghao ; Cao, Hongcui ; Li, Huafei ; Yang, Yanlei ; Zhou, Shumin ; Caruso, Calogero ; Jin, Kunlin ; Wang, Xiaoyue ; Zhu, Jiaqi ; Peng, Shuang ; Xu, Haoying ; Hou, Wei ; Ulfhake, Brun ; Deng, Luchan ; Wang, Shihua ; Brown-Borg, Holly M ; Li, Zhe ; Han, Qin ; Gao, Jinming ; Wei, Feng ; Li, Hongling ; Liu, Yan
Abstract:The infusion of coronavirus disease 2019 (COVID-19) patients with mesenchymal stem cells (MSCs) potentially improves clinical symptoms, but the underlying mechanism remains unclear. We conducted a randomized, single-blind, placebo-controlled (29 patients/group) phase II clinical trial to validate previous findings and explore the potential mechanisms. Patients treated with umbilical cord-derived MSCs exhibited a shorter hospital stay (P = 0.0198) and less time required for symptoms remission (P = 0.0194) than those who received placebo. Based on chest images, both severe and critical patients treated with MSCs showed improvement by day 7 (P = 0.0099) and day 21 (P = 0.0084). MSC-treated patients had fewer adverse events. MSC infusion reduced the levels of C-reactive protein, proinflammatory cytokines, and neutrophil extracellular traps (NETs) and promoted the maintenance of SARS-CoV-2-specific antibodies. To explore how MSCs modulate the immune system, we employed single-cell RNA sequencing analysis on peripheral blood. Our analysis identified a novel subpopulation of VNN2+ hematopoietic stem/progenitor-like (HSPC-like) cells expressing CSF3R and PTPRE that were mobilized following MSC infusion. Genes encoding chemotaxis factors — CX3CR1 and L-selectin — were upregulated in various immune cells. MSC treatment also regulated B cell subsets and increased the expression of costimulatory CD28 in T cells in vivo and in vitro. In addition, an in vivo mouse study confirmed that MSCs suppressed NET release and reduced venous thrombosis by upregulating kindlin-3 signaling. Together, our results underscore the role of MSCs in improving COVID-19 patient outcomes via maintenance of immune homeostasis.